<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80537">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01798147</url>
  </required_header>
  <id_info>
    <org_study_id>SIRT-TACE-CCC-Mainz-1</org_study_id>
    <nct_id>NCT01798147</nct_id>
  </id_info>
  <brief_title>Selective Internal Radiotherapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Cholangiocellular Carcinoma (CCC).</brief_title>
  <official_title>Selective Internal Radiotherapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Cholangiocellular Carcinoma (CCC).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johannes Gutenberg University Mainz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johannes Gutenberg University Mainz</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Selective Internal Radiotherapy is superior to Transarterial Chemoembolisation for the
      treatment of intrahepatic cholangiocellular carcinoma (CCC).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>at the end of study</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>at the end of study</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>at the end of study</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Intrahepatic Cholangiocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>DEB TACE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug eluting Beads (DC Beads) loaded with Doxorubicin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SIRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Selective Internal Radiotherapy using Yttrium 90 loaded resin beads (Sir Spheres)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>DEB TACE</intervention_name>
    <description>DEB TACE every 6 weeks until either no viable tumor or endpoint reached.</description>
    <arm_group_label>DEB TACE</arm_group_label>
    <other_name>Chemoembolisation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SIRT</intervention_name>
    <description>Selective Internal Radiotherapy once at the beginning of the study. Follow up until endpoint.</description>
    <arm_group_label>SIRT</arm_group_label>
    <other_name>Radioembolisation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥18 years

          -  Intrahepatic CCC, proven by histology or by typical morphology in cross sectional
             imaging and elevated tumor markers (CEA or CA 19-9)

          -  Tumor confined to the liver

          -  At least one measurable lesion in magnetic resonance imaging (MRI)

          -  Tumor load ≤ 50%

          -  Preserved liver function (Child Pugh A and B)

          -  ECOG performance status ≤2

        Exclusion Criteria:

          -  Patients feasible for curative treatment (e.g. resection or local ablation)

          -  Previous TACE or SIRT

          -  Chemotherapy during the last 4 weeks

          -  Child Pugh stage C

          -  ECOG Performance Status &gt;1

          -  Tumor involvement &gt;50% of the liver

          -  Extrahepatic tumor

          -  Serum Bilirubin &gt;2.0 mg/dl; Serum Albumin 2.8 g/dl, Serum Creatinine &gt;2 mg/dl;
             Leukocytes &lt;3000/ml; Thrombocytes &lt;50000/ml

          -  Clinically apparent ascites (ascites only in CT/MRI is no exclusion criteria)

          -  Esophageal bleeding during the last 3 months

          -  Hepatic encephalopathy

          -  Transjugular intrahepatic portosystemic shunt (TIPS)

          -  Infiltration or occlusion of the main portal vein

          -  Hepatofugal blood flow in the portal vein

          -  Hepatopulmonary shunt ≥ 20% in the macroaggregated albumin scan (MAA-scan)

          -  Contraindications against angiography

          -  Gravidity
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Roman Kloeckner, MD</last_name>
    <phone>++49613117</phone>
    <phone_ext>2019</phone_ext>
    <email>roman.kloeckner@unimedizin-mainz.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Diagnostic and Interventional Radiology</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roman Kloeckner, MD</last_name>
      <phone>++49613117</phone>
      <phone_ext>2019</phone_ext>
      <email>roman.kloeckner@unimedizin-mainz.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 1, 2014</lastchanged_date>
  <firstreceived_date>February 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johannes Gutenberg University Mainz</investigator_affiliation>
    <investigator_full_name>Michael Bernhard Pitton</investigator_full_name>
    <investigator_title>Consultant</investigator_title>
  </responsible_party>
  <keyword>Cholangiocellular Carcinoma</keyword>
  <keyword>TACE</keyword>
  <keyword>SIRT</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
